Neuland Laboratories Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ylrzsvlt63b0cbc4dkvoj4ps.pdf

Key Takeaways


FY24 Performance & the Normalization Ahead

Sucheth Davuluri: "I think everything we are making in terms of commentary about FY25 and the year beyond, is we are being very realistic. We don't necessarily intend to downplay anything."

The Pipeline Lag & Multi-Year Outlook

Saharsh Davuluri: "If you see the growth that we have achieved in FY23 and FY24 was actually as a result of the new projects we added in FY19 and FY20. So therefore, we would appreciate that there's always going to be a lag between the performance of the year versus the effort of getting a new business."

Biosecure Act & Geopolitical Tailwinds

Saharsh Davuluri: "We actually see less competition for us in China. And in that sense, the European CDMOs, European API makers are always a credible threat."

GLP-1 & New Molecule Opportunities

Saharsh Davuluri: "I think one GLP-1, CDMO opportunity is very limited because all these companies who are the innovators are securing their own API supply chains by building, making them in-house."

Capex, Capacity & Balance Sheet


Customer & Competitive Dynamics

Saharsh Davuluri: "The decision of working in India versus keeping a molecule in the West is more of a, I've seen that it's more of a board decision of the innovator company. It's got less to do with whether the outsourcing managers or the CMC groups have faith in Neuland or not."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth moderationModest growth in FY25, far better growth in FY26 and FY27 based on current pipeline projectionsFY25 / FY26-27
Medium-term growth target20% kind of growth over a 4-5 year period, not linear year-on-year4-5 year horizon
Margin normalizationNormalization to some extent due to investments and input cost increases; business mix expected to remain steady and gradually improveFY25
Working capitalTarget 120 days, fairly confident of achievingNot specified
Baseline capex₹100-plus crores per year, opportunistic for growth capexOngoing
New project inflow increaseTotal number of projects should increase in the next 12 monthsNext 12 months
Difelikefalin DMF filingFirst active GDS project, DMF expected to be filed later this yearCY24
GLP-1 GDS DMF filingSecond active GDS project, DMF filing perhaps in 20262026

Key Metrics

MetricQ4 FY24
Total income (FY24)₹1,571.1 cr, +30.8% YoY
Profit after tax₹67.6 cr, vs ₹84.5 cr in Q4 FY23
EPS₹52.7 per share
EBITDA margin (FY24)30%, up from 23% in FY23 and 15% in FY22
Gross marginCompared to 59.8% in Q3 FY24
CMS revenue share (FY24)Close to 50% of total revenues
Operating expenses growth~18% as per plan, rest variable; total increase ~21% YoY and ~23% QoQ
Net debtNegative ₹32.6 cr
Working capital cycle122 days, improved from 141 days at end of March 2023
Capex (FY24)₹143.7 cr invested
Capex guidance baseline₹100-plus cr per year
Peak cash flow (FY24)₹116.4 cr
Debt reduction (FY24)₹39.4 cr
Total active projects88 in FY24, vs 76 in FY20
Commercial CMS projects18 (8+10), none involve biologics